ScoreWhy is Chiome Bioscience, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate 5.48% of over the last 5 years
3
Flat results in Dec 25
- NET SALES(HY) At JPY 341.49 MM has Grown at -33.96%
- CASH AND EQV(HY) Lowest at JPY 2,210.77 MM
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -31.33%, its profits have risen by 24.1%
5
Below par performance in long term as well as near term
- Along with generating -31.33% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Chiome Bioscience, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Chiome Bioscience, Inc.
-31.33%
-0.43
44.40%
Japan Nikkei 225
36.73%
1.30
28.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.73%
EBIT Growth (5y)
5.48%
EBIT to Interest (avg)
-775.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.44
Tax Ratio
0.29%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.66
EV to EBIT
-8.66
EV to EBITDA
-8.67
EV to Capital Employed
37.68
EV to Sales
10.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-434.83%
ROE (Latest)
-55.91%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at JPY -451.73 MM
ROCE(HY)
Highest at -64.61%
RAW MATERIAL COST(Y)
Fallen by -14.08% (YoY
NET SALES(Q)
At JPY 223.47 MM has Grown at 22.79%
-9What is not working for the Company
NET SALES(HY)
At JPY 341.49 MM has Grown at -33.96%
CASH AND EQV(HY)
Lowest at JPY 2,210.77 MM
Here's what is working for Chiome Bioscience, Inc.
Net Profit
Higher at JPY -451.73 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Net Sales
At JPY 223.47 MM has Grown at 22.79%
over average net sales of the previous four periods of JPY 182 MMMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Raw Material Cost
Fallen by -14.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 2.5 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Depreciation
At JPY 2.5 MM has Grown at 102.83%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (JPY MM)
Here's what is not working for Chiome Bioscience, Inc.
Cash and Eqv
Lowest at JPY 2,210.77 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
